BHST (BioHarvest Sciences) Long-Term Debt: $0.79 Mil (As of Mar. 2026)


BHST BioHarvest Sciences Inc BHST
63 GF Score
Price $2.87
GF Value $8.58
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioHarvest Sciences Long-Term Debt?

BioHarvest Sciences BHST -1.37% 63 Long-Term Debt is $0.79 Mil as of Mar. 2026. GuruFocus rates BHST with a GF Score™ of 63/100 and a GF Value™ of $8.58 (Possible Value Trap). The stock has 4 warning signs investors should review.

BioHarvest Sciences's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.79 Mil.

BioHarvest Sciences's quarterly Long-Term Debt increased from Sep. 2025 ($2.34 Mil) to Dec. 2025 ($2.42 Mil) but then declined from Dec. 2025 ($2.42 Mil) to Mar. 2026 ($0.79 Mil).

BioHarvest Sciences's annual Long-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($2.42 Mil).

BioHarvest Sciences  (NAS:BHST) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioHarvest Sciences Long-Term Debt Related Terms

BioHarvest Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BioHarvest Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioHarvest Sciences Long-Term Debt Chart

BioHarvest Sciences Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.42

BioHarvest Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.26 2.34 2.42 0.79
BHST
63GF Score
BioHarvest Sciences Inc BHST
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.79 Mil mean?
BioHarvest Sciences (BHST) has a Long-Term Debt of $0.79 Mil as of Mar. 2026.
Is BioHarvest Sciences' Long-Term Debt too high?
BioHarvest Sciences' current Long-Term Debt is $0.79 Mil. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Long-Term Debt compare to BRID and BOF?
BioHarvest Sciences' Long-Term Debt of $0.79 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Consumer Packaged Goods company?
A good Long-Term Debt depends on the Consumer Packaged Goods industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BioHarvest Sciences's current Long-Term Debt is $0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.58, compared to a current price of $2.87 — trading 66.6% below its estimated fair value. The current Long-Term Debt is $0.79 Mil. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Long-Term Debt is $0.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioHarvest Sciences (BHST) Overvalued in 2026?

Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued. The current stock price of $2.87 is trading 66.6% below its estimated GF Value™ of $8.58. GuruFocus considers BioHarvest Sciences to be Possible Value Trap.

Key valuation signals for BHST:

  • Long-Term Debt: $0.79 Mil
  • GF Value™: $8.58 vs. price of $2.87 (66.6% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioHarvest Sciences Business Description

Other Exchanges 8MV0:Germany
Address 1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score

Get the complete analysis for BHST

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.87
Price
$8.58
GF Value